Heartseed

  • NEWS
  • PIPELINE
  • TECHNOLOGY
  • ABOUT US
    • CEO Message
    • Purpose
    • Company Profile
    • Management
  • Mission & Values
  • IR
    • IR News
    • Management
    • IR Library
    • Stock Information
    • Other Contents
  • CONTACT
  • JP/EN
  1. HOME
  2. NEWS
  3. PR

PR

2021323

PR Heartseed Initiates Ph1/2 Clinical Trial of iPSC-derived Cardiomyocyte Spheroids (LAPiS Study) in Japan

202131

PR Heartseed named "Minister of Science and Technology Policy Award"  at Japan Venture Awards 2021

20201130

PR Heartseed Named "Healthcare Company of the Year 2020" by Healthcare Insights Magazine

2020310

PR Announced Capital and Business Alliance with MEDIPAL HOLDINGS

2020310

PR Announced Capital Alliance with ITOCHU CHEMICAL FRONTIER

20191122

PR Heartseed raises $26 Million in Series B Funding

2018918

PR Heartseed Inc. was selected as one of the subsidy program of Japan Agency for Medical Research and Development (AMED), supporting Research Project for Practical Applications of Regenerative Medicine

2018730

PR Announced that 800 million yen was raised through third-party allocation of new shares from Angel Bridge, Astellas Venture Management and Shibuya Cooperation

2016314

PR Announced that 100 million yen was raised through third-party allocation of new shares from Angel Bridge

1 2 3

COMPANY OVERVIEW

To transform treatment of severe heart failure by delivering cardiac regenerative medicine, Heartseed Inc. was founded in 2015. It has also been developing technologies to expand the access of RM.

Company name
Heartseed Inc.
Head Office
Seavans South Building 5F, 1-2-3 Shibaura, Minato-ku, Tokyo 105-0023, JAPAN
Contact
contact@heartseed.jp

MORE VIEW

MENU

  • Home
  • News
  • PIPELINE
  • TECHNOLOGY
  • About us
  • Mission & Values
  • IR
  • Contacts

language

  • English
  • Japanese

GO TO TOP

Copyright © All Rights Reserved HEARTSEED HEARTSEED